Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lyra Therapeutics Inc 480 ARSENAL STREET WATERTOWN MA 02472 USA

https://lyratherapeutics.com P: 617-393-4600

Description:

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and consistently deliver medicines directly to the affected tissue. Its initial product candidates consist LYR-210 and LYR-220 which are in clinical stage. Lyra Therapeutics Inc. is based in Watertown, Mass.

Key Statistics

Overview:

Market Capitalization, $K 282,268
Enterprise Value, $K 259,918
Shares Outstanding, K 60,965
Annual Sales, $ 1,560 K
Annual Net Income, $ -62,680 K
Last Quarter Sales, $ 150 K
Last Quarter Net Income, $ -15,160 K
EBIT, $ -67,120 K
EBITDA, $ -70,340 K
60-Month Beta 0.31
% of Insider Shareholders 17.42%
% of Institutional Shareholders 95.62%
Float, K 50,345
% Float 82.58%
Short Volume Ratio 0.24

Growth:

1-Year Return 53.04%
3-Year Return -44.95%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.35 on 04/30/24
Latest Earnings Date 05/10/24
Earnings Per Share ttm -1.26
EPS Growth vs. Prev Qtr -59.09%
EPS Growth vs. Prev Year 20.45%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

LYRA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -77.34%
Return-on-Assets % -51.00%
Profit Margin % -4,017.95%
Debt/Equity 0.00
Price/Sales 205.43
Price/Cash Flow N/A
Price/Book 3.30
Book Value/Share 1.56
Interest Coverage -2.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar